Literature DB >> 33961969

The Risks and Benefits of Myopia Control.

Mark A Bullimore1, Eric R Ritchey2, Sunil Shah3, Nicolas Leveziel4, Rupert R A Bourne5, D Ian Flitcroft6.   

Abstract

OBJECTIVE: The prevalence of myopia is increasing around the world, stimulating interest in methods to slow its progression. The primary justification for slowing myopia progression is to reduce the risk of vision loss through sight-threatening ocular pathology in later life. The paper analyzes whether the potential benefits of slowing myopia progression by one diopter justify the potential risks associated with treatments.
METHODS: First, the known risks associated with various methods of myopia control are summarized, with emphasis on contact lens wear. Based on available data, the risk of visual impairment and predicted years of visual impairment are estimated for a range of incidence levels. Next, the increased risk of potentially sight threatening conditions associated with different levels of myopia are reviewed. Finally, a model of the risk of visual impairment as a function of myopia level is developed, and the years of visual impairment associated with various levels of myopia and the years of visual impairment that could be prevented with achievable levels of myopia control is estimated.
RESULTS: Assuming an incidence of microbial keratitis between 1 and 25 per 10,000 patient years and that 15% of cases result in vision loss, leads to the conclusion that between 38 and 945 patients need to be exposed to five years of wear to produce 5 years of vison loss. Each additional diopter of myopia is associated with a 57%, 20%, 21%, and 30% increase in the risk of myopic maculopathy, open angle glaucoma, posterior subcapsular cataract, and retinal detachment, respectively. The predicted mean years of visual impairment ranges from 4.42 in a -3 D myope to 9.56 in a -8 D myope and a one diopter reduction would lower these by 0.74 and 1.22 respectively.
CONCLUSIONS: The potential benefits of myopia control outweigh the risks: the number needed to treat to prevent 5 years of visual impairment is between 4.1 and 6.8 while fewer than 1 in 38 will experience a loss of vision as a result of myopia control.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Year:  2021        PMID: 33961969     DOI: 10.1016/j.ophtha.2021.04.032

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  6 in total

1.  Short-term effect of 0.01% atropine sulphate eye gel on myopia progression in children.

Authors:  Shi-Yin Pan; Yang-Zheng Wang; Jun Li; Xue-Hui Zhang; Jin Wang; Xiu-Ping Zhu; Xiang-Hua Xiao; Jun-Tian Liu
Journal:  Int J Ophthalmol       Date:  2022-07-18       Impact factor: 1.645

2.  Sports and Myopia: An Investigation on the Prevalence and Risk Factors of Myopia in Young Sports-Related Groups in Tianjin, China.

Authors:  Mingxue Zhang; Zhiyong Sun; Xinlei Zhu; Haokun Zhang; Yun Zhu; Hua Yan
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-06-01       Impact factor: 4.925

3.  The impact of spectacle lenses for myopia control on visual functions.

Authors:  Yi Gao; Ee Woon Lim; Adeline Yang; Björn Drobe; Mark A Bullimore
Journal:  Ophthalmic Physiol Opt       Date:  2021-09-16       Impact factor: 3.992

4.  Will treating progressive myopia overwhelm the eye care workforce? A workforce modelling study.

Authors:  Gareth Lingham; James Loughman; Stella Kuzmenko; Matilda Biba; Daniel Ian Flitcroft
Journal:  Ophthalmic Physiol Opt       Date:  2022-06-21       Impact factor: 3.992

5.  The Refractive Error and Vision Impairment Estimation with Spectacle Data Study.

Authors:  Michael Moore; James Loughman; John S Butler; Arne Ohlendorf; Siegfried Wahl; Daniel I Flitcroft
Journal:  Ophthalmol Sci       Date:  2021-12-17

6.  A Comparative Study of Traditional Scleral Buckling to a New Technique: Guarded Light Pipe with Heads-Up Three-Dimensional Visualization.

Authors:  Grace Baldwin; Jared T Sokol; Cassie A Ludwig; John B Miller
Journal:  Clin Ophthalmol       Date:  2022-09-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.